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Abstract
Background:  The development of novel chemotherapeutic agents in colorectal cancer has
improved survival. Following initial response to chemotherapeutic strategies many patients develop
refractory disease. This poses a significant challenge common to many cancer subtypes. Newer
agents such as Bevacizumab have successfully targeted the tyrosine kinase receptor epidermal
growth factor receptor in metastatic colorectal cancer. Human epidermal growth factor receptor-
2 is another member of the tyrosine kinase receptor family which has been successfully targeted in
breast cancer. This may play a role in colorectal cancer. We conducted a clinicopathological study
to determine if overexpression of human epidermal growth factor receptor-2 is a predictor of
outcome in a cohort of patients with colorectal cancer.
Methods:  Clinicopathological data and paraffin-embedded specimens were collected on 132
consecutive patients who underwent colorectal resections over a 24-month period at Mayo
General Hospital. Twenty-six contained non-malignant disease. Her-2/neu protein overexpression
was detected using immunohistochemistry (IHC). The HER-2 4B5 Ventana monoclonal antibody
was used. Fluorescent insitu hybridisation (FISH) was performed using INFORM HER-2/Neu Plus.
Results were correlated with established clinical and pathological predictors of outcome including
TNM stage. Statistical analysis was performed using SPSS version 11.5.
Results: 114 were HER-2/Neu negative using IHC, 7 showed barely perceptible positivity (1+), 9
showed moderate staining (2+) and 2 were strongly positive (3+). There was no correlation with
gender, age, grade, Dukes' stage, TNM stage, time to recurrence and 5-year survival (p > 0.05).
FISH was applied to all 2+ and 3+ cases as well as some negative cases selected at random. Three
were amplified (2 were 3+ and 1 was 2+). Similarly, HER-2 gene overexpression did not correlate
with established prognostic indicators.
Conclusion: HER-2 protein is over expressed in 11% of colorectal cancer patients. The gene
encoding HER-2 is amplified in 3% of cases. Overexpression of HER-2 is not a predictor of
outcome. However, patients who over express HER-2 may respond to Herceptin therapy.
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Background
Colorectal cancer is the second commonest cause of can-
cer-related death in the United States and the Western
World [1,2]. The 5-year relative survival rate is approxi-
mately 45% demonstrating an improvement from 30
years ago when the survival rate was 30%. Modifications
in adjuvant therapy have been central to this observed
improvement. Cytotoxic agents such as irinotecan and
oxaliplatin have improved survival while the develop-
ment of monoclonal antibodies against growth factor
receptors has augmented their effects. A significant
improvement in the median overall survival in patients
with metastatic colorectal cancer was achieved when Bev-
acizumab (a monoclonal antibody directed against the
tyrosine kinase receptor, VEGF) was added to a chemo-
therapy regimen of oxaliplatin and 5-fluorouracil (P =
0.0024) [3].
The human epidermal growth factor receptor-2 (HER-2) is
another member of the tyrosine kinase receptor super-
family. HER-2 protein is also known as c-erb-2 or neu. Sla-
mon et al demonstrated that this is over expressed in 30%
of patients with breast cancer [4]. Trastuzumab (a mono-
clonal antibody directed against HER-2) has impacted
upon survival in approximately 20% of patients who over
express HER-2 and is now established therapy in the treat-
ment of metastatic breast cancer [5]. Other members of
the family include HER-1, HER-3 and HER-4. They all
possess an extracellular ligand binding domain, a mem-
brane spanning region and a cytoplasmic domain with
tyrosine kinase activity. It is understood that HER-2 het-
erodimerises with other HER receptors unlike the other
family receptors which possess a direct binding ligand. In
tumour model systems overexpression of the HER-2 gene
correlates with mitogenesis, malignant transformation,
increased cell motility, invasion and metastasis [6]. Over-
expression of HER-2/neu in breast cancer is a useful
marker of outcome. It correlates with a poor prognosis.
Moreover, it is used to predict patient response to adju-
vant chemotherapy and endocrine therapy and to select
patients for immunotherapy with targeted monoclonal
antibody therapy [7,8]. Intuitively, patients who over
express HER-2 should respond to Trastuzumab (Hercep-
tin) therapy independent of the tissue of origin of the can-
cer. Herceptin has been shown to inhibit colony
formation of the HCA-colon cancer cell line and HCA-7
tumour xenografts [9].
Several studies have reported a variety of protein and gene
expression levels in colorectal cancer. Similarly there is a
wide variability in the published literature in relation to
survival benefit. This variety is predominantly due to a
lack of standardisation of detection methods. Some stud-
ies have demonstrated up to 70% overexpression of cyto-
plasmic HER-2 [10,11]. Cytoplasmic HER-2 is incapable
of transmitting the strong mitogenic signal via heterodim-
erisation of other members of the EGFR family. Others
have reported membranous overexpression in 50% of
patients with colorectal cancer [12]. The current study
employed the monoclonal antibody 4B5 which is used to
determine suitability for Herceptin therapy in breast can-
cer in our unit. We employed a FISH technique validated
for therapeutic use in breast cancer. The aim of the current
study was to establish the presence of membranous HER-
2 protein overexpression in colorectal cancer, determine if
there is gene amplification and establish whether overex-
pression of HER-2 is a predictor of outcome.
Methods
A total of 132 patients were included for analysis. These
represented consecutive patients who underwent colorec-
tal resections at Mayo General Hospital from January 1st,
1998 to December 31st, 1999. The study was approved by
the institutions' ethics committee. The study group con-
sisted of 48 females and 84 males. The mean age was 67
years (range = 29 – 89 years). None of the patients had
undergone preoperative chemotherapy or radiotherapy.
The medical records of these patients were reviewed spe-
cifically regarding patient demographics, therapeutic
strategies, pathological data and survival. Patients were
followed up in accordance with international guidelines.
Pathological subtypes included (number): adenomatous
polyp (10), diverticulosis (7), IBD (5), ischaemia (2), Car-
cinoid (1), angiodysplasia (1) and colorectal cancer
(106). Each specimen was formalin fixed and embedded
in paraffin. Prior to inclusion each slide was verified by a
pathologist.
Immunohistochemistry
Staining for HER-2/neu protein was performed on 5 μm
(micro-meter) thick slides using the Ventana PATHWAY
HER-2 (4B5) mouse monoclonal antibody (Ventana
Medical Systems, Tuscon, USA). There is significant corre-
lation of staining between the CB11 antibody which is
FDA approved and the HerceptTest. In our institution the
4B5 monoclonal antibody is utilised which is equally
valid and used to determine suitability for herceptin ther-
apy in breast cancer. Following deparaffinisation, antigen
retrieval and incubation with blocking agent the 4B5
monoclonal antibody directed against HER-2/neu was
incubated using an automated slide staining device. At the
end of each incubation step, the Ventana automated slide
stainer washed the sections and applied a cover slip to
minimise evaporation of aqueous reagent. The primary
antibody was then localised by a biotin-conjugated sec-
ondary antibody formulation that recognises mouse
immunoglobulins. The specific antibody-secondary anti-
body-avidin/streptavidin-enzyme complex was then visu-
alised with a diaminobenzidine stain. They were
subsequently counterstained with haematoxylin, dehy-BMC Cancer 2009, 9:1 http://www.biomedcentral.com/1471-2407/9/1
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drated and cover slips were mounted. Slides were viewed
by two independent pathologists blinded to each others
findings. Negative controls were created by the omission
of primary antibody and replacement with phosphate
buffered saline (PBS). Invasive breast cancer specimens
were utilised as positive controls. Slides were scored using
a four-tiered scoring system according to manufacturer's
guidelines. Score 0 is defined as no staining or membra-
nous staining in < 10% of tumour cells. Score 1+ is
defined as faint membrane staining in > 10% of tumour
cells. Score 2+ is defined as weak to moderate staining in
> 10% of tumour cells and a score of 3+ is defined as
strong staining of the entire membrane in > 10% of
tumour cells. A score of 0 or 1+ was considered negative
while a score of 2+ or 3+ was considered positive. Cyto-
plasmic staining may have been present but was not
included in the determination of positivity.
Fluorescent insitu hybridisation (FISH) was applied to all
2+ and 3+ cases as well as a random selection of negative
cases. This was conducted using the INFORM HER-2/neu
plus probe kit. This technique utilises two fluorescent
radiolabelled probes: LSI HER-2 (specific to the HER-2
gene locus) and CEP 17 (specific to the alpha satellite
DNA sequence at the centromeric region of chromosome
17). The former stains orange while the latter stains green.
The slides were evaluated for the HER-2 gene using a flu-
orescent microscope where a cell is considered to show
amplification if > 4 signals of HER-2/neu is detected.
Statistical analysis was performed using SPSS version 11.5.
HER-2 protein and gene expression were correlated with
clinicopathological parameters and 5-year cancer-related
survival using chi-squared testing. Patients who died within
30 days of surgery were excluded from the 5-year cancer-
related survival. Patients were followed up for a median of
48.5 months (Range = 1–121 months). For all tests, P <
0.05 was considered to be statistically significant.
Results
One hundred and thirty two consecutive patients were
included in the study. Twenty six of these had non-malig-
nant disease.
Immunhistochemical detection of HER-2/neu 
overexpression
HER-2/neu overexpression was not detected in benign tis-
sues. Ten percent of patients exhibited a score of 2+ or 3+
and were considered positive as shown in Table 1/Figure
1. Positive staining was found in 2 (7%) of the 27 rectal
carcinomas and 9 (11%) of the 79 colon cancers. The
interobserver agreement was 0.91 as illustrated in Table 2.
The clinical and pathological features of these patients are
presented in Table 3. Tumours that over expressed HER-2
were predominantly poorly differentiated and Dukes C.
This correlation was not significant (p = 0.72). There was
no correlation between HER-2/neu overexpression and
age, gender, lymphovascular invasion, TNM stage,
perineural invasion or tumour size.
HER-2/neu gene amplification
FISH analysis demonstrated gene amplification in 2 rectal
(both 3+) and one colon (2+) cancer (Table 1 & Figure 2).
In randomly selected tumours which demonstrated nega-
tive staining for HER-2 (0+ and 1+) none revealed ampli-
fication of the gene. There was no correlation between
gene expression and clinical or pathological parameters.
Correlation with survival
This was carried out on patients with cancer-related death
who died a minimum of 30 days following resection. The
5-year survival for well, moderately and poorly differenti-
ated cancer was 78%, 58% and 42% respectively. The 5-
year survival by Dukes' stage for A, B, C, D were 86%,
78%, 53% and 13% respectively. There was no correlation
Immunohistochemical staining for HER-2/neu (Haematoxylin  & eosin, magnification × 200) Figure 1
Immunohistochemical staining for HER-2/neu (Hae-
matoxylin & eosin, magnification × 200). Breast cancer 
cells were used as a positive control (not shown). a.) Faint 
membrane staining is shown in > 10% of tumour cells (1+). 
b.) Weak to moderate staining of the entire membrane (2+). 
c.) Strong staining of the entire membrane in > 10%.
ab
c
Table 1: Overexpression of HER-2/neu gene and protein in 
colorectal cancer
Immunohistochemical score n (%) FISH amplification n (%)
0 0 (0) > 4 signals/cell 0
1+ 7 (7) > 4 signals/cell 0
2+ 9 (8) > 4 signals/cell 1
3+ 2 (2) > 4 signals/cell 2 (2)
HER-2 protein was not over expressed in non-malignant colorectal 
specimens. The HER-2/neu gene was not over amplified in selected 
non-malignant specimens.BMC Cancer 2009, 9:1 http://www.biomedcentral.com/1471-2407/9/1
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between HER-2/neu protein overexpression and disease-
free or overall survival as illustrated in Figure 3. (p = 0.9:
p = 0.8 respectively)
Discussion
EGFR and HER-2/neu are therapeutic targets in a variety of
malignancies due to their overexpression. These can be
targeted utilising antibodies directed against the extracel-
lular domains or tyrosine kinase inhibitors. These strate-
gies have been successful in the area of breast cancer and
EGFR has been effective in the treatment of metastatic
colorectal cancer. Not all patients who overexpress HER-
2/neu respond to treatment with Herceptin (25%). The
published data report varying rates of HER-2 overexpres-
sion in colorectal cancer. The current study was under-
taken with a view to establishing a potential role for
Herceptin therapy in colorectal cancer by utilising an
internationally validated detection method.
Our data demonstrates that HER-2 protein is overex-
pressed in 11% of cases while the gene is amplified in 3%.
While this did not correlate with prognostic indices or sur-
vival all cases were poorly differentiated Dukes' C cancers.
A lack of consistency between the two techniques has
been previously described [12]. This may be interpreted
by the hypothesis that protein expression is achieved by
transcriptional activation of genes other than the HER-2
gene. Both techniques are used in determining treatment
response in breast cancer provided the technique is vali-
dated. The wide range of protein (0–70%) and gene (0–
30%) expression in colorectal cancer is largely due to the
lack of standardisation of the detection methods [13-18].
High protein rates are often reported due to detectable
cytoplasmic HER-2 which is not targeted by Herceptin.
Immunohistochemistry is relatively inexpensive, widely
available, easy to preserve, less time consuming and
requires a routine microscope. Assessment by two pathol-
ogist with minimal interobserver variability improves the
accuracy. The variability in antigen retrieval, antibody
type and inconsistent storage of paraffin embedded tis-
sues limits it accuracy. FISH uses a more objective scoring
system, is automated and has a sensitivity of 96% and a
specificity of 100% [19]. However, it is expensive, time
consuming, requires a fluorescent microscope and it is dif-
ficult to distinguish tumor cells from normal stromal
cells. Emerging results suggests that FISH is more accurate
than immunohistochemistry in predicting patient out-
come and response to herceptin [20].
Table 2: Calculation of the interobserver agreement (kappa coefficient)
Pathologist 2 Total
1+ 2+ 3+ 1.00
Pathologist 1 1+ Count (n) 7 1 0 8
Pathologist 1 (%) 87.5 12.5 0 100
Pathologist 2 (%) 100 11.1 0 44.4
% of Total 38.9 5.6 0 44.4
2+ Count (n) 0 8 0 8
Pathologist 1 (%) 0 100 0 100
Pathologist 2 (%) 0 88 0 44.4
% of Total 0 44 0 44.4
3+ Count (n) 0 0 2 2
Pathologist 1 (%) 0 0 100 100
Pathologist 2 (%) 0 0 100 11.1
% of Total 0 0 11.1 11.1
Total Count (n) 7 9 2 18
Pathologist 1 (%) 38.9 50 11.1 100
Pathologist 2 (%) 100 100 100 100
% of Total 38.9 50 11.1 100
Symmetric measures
Value Standard error (a) Approximate T (b) Approximate significance
Kappa coefficient 0.906 0.092 4.894 0.00
Number of valid cases (n) 18
a Not assuming the null hypothesis.
b Using the asymptotic standard error assuming the null hypothesis.BMC Cancer 2009, 9:1 http://www.biomedcentral.com/1471-2407/9/1
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We have not demonstrated that overexpression of HER-2
predicts survival however we have shown that it tends to
appear in a more aggressive phenotype. Lazaris et al iden-
tified a 36% expression rate and a role as an predictor of
poor outcome [21]. Similarly Park et al reported a 47%
protein expression rate using a polyclonal antibody
(Zymed laboratories, South San Francisco, USA) and cor-
related overexpression with a higher incidence of postop-
erative recurrence [12]. Conversely, Schuell et al
demonstrated an overexpression rate of 4% using the val-
idated HercepTest. This did not correlate with survival
[22,23]. The HER-2 overexpression rate of 11% demon-
strated in the current study may approach significance in
relation to poor prognosis in a larger patient cohort. The
methodology utilised is internationally validated in
selecting patients who undergo treatment with Herceptin
for metastatic breast cancer.
A phase II trial in conjunction with the National Cancer
Institute demonstrated low levels of HER-2 overexpres-
sion (8%) however when these patients with metastatic
colorectal cancer were treated with Herceptin in combina-
tion with irinotecan 5 of 7 patients who overexpressed it
responded to therapy [24]. Under the current staging sys-
tem within a specific stage a variable spectrum of outcome
exists (> 25% in stage II disease). The development of
gene signatures may unfold subsets within a given stage
who have a worse prognosis and therefore require differ-
ent adjuvant therapies [25]. One of these genes may be the
HER-2/neu gene.
Conclusion
We have not demonstrated compelling evidence support-
ing a potential role for Herceptin in colorectal carcinoma
as shown in breast cancer. Similarly we have not revealed
that it is an important prognostic indicator. Some patients
who overexpress HER-2 (11%) will respond to Herceptin.
The evolution of signature genes in colorectal cancer and
molecular profiling may facilitate identification of the
small subset of patients overexpressing HER-2 who will
have a favourable response to Herceptin therapy.
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Table 3: Clinicopathological features of patients with colorectal 
cancer (n = 106)
Variable
Gender (number (%))
Male 71 (67)
Female 35 (33)
Age (Range in years) 67 (29 _89)
Dukes stage (number (%))
A1 4  ( 1 3 )
B2 1  ( 2 0 )
C5 5  ( 5 2 )
D1 6  ( 1 5 )
Histological grade (number (%))
Well 14 (13)
Moderate 65 (61)
Poor 27 (26)
Site of tumour (number (%))
Right colon 18 (17)
Transverse colon 6 (6)
Left colon 55 (52)
Rectum 27 (25)
5-year survival (%) 48
Cancer specific 5-year survival (%) 51
Fluorescence in situ hybridisation of HER-2 gene amplifica- tion Figure 2
Fluorescence in situ hybridisation of HER-2 gene 
amplification. Amplified HER-2/neu gene forms multiple 
scattered signals as illustrated with the white arrows.
Kaplan-Meier plot for: a.) disease-free and b.) overall survival  in 106 colorectal cancer patients comparing HER-2 positive  and HER-2 negative patients Figure 3
Kaplan-Meier plot for: a.) disease-free and b.) overall 
survival in 106 colorectal cancer patients comparing 
HER-2 positive and HER-2 negative patients. There 
was no significant correlation with both parameters and 
HER-2 overexpression.
P=0.8
HER-2  positive
HER-2 Negative
P=0.9
HER-2  positive
b.
HER-2 Negative
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